Literature DB >> 8010166

Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age.

J D Collier1, R Curless, M F Bassendine, O F James.   

Abstract

A retrospective review of 110 cases of hepatocellular carcinoma (HCC) from the North East of England was undertaken to examine clinical features and prognosis in the 52 patients 65 years of age or more at presentation in comparison with 58 patients under 65. Symptoms and signs at the time of presentation were similar in the two age groups. Only 25% of patients were known to be cirrhotic at the time of presentation, but this increased to 75% after investigation. Although tumour stage at diagnosis was no worse in the elderly group, these patients received less intensive investigation and were significantly more likely to receive conservative therapy (p = 0.03). Although median survival was significantly worse in those aged > or = 65 years than in those < 65 years (10.5 and 18.5 weeks respectively; p = 0.02) this adverse effect disappeared when adjusted for the effects of treatment.

Entities:  

Mesh:

Year:  1994        PMID: 8010166     DOI: 10.1093/ageing/23.1.22

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  11 in total

Review 1.  Parenchymal liver disease in the elderly.

Authors:  O F James
Journal:  Gut       Date:  1997-10       Impact factor: 23.059

2.  The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).

Authors:  Hilda Wong; Yuen Fong Tang; Tzy-Jyun Yao; Joanne Chiu; Roland Leung; Pierre Chan; Tan To Cheung; Albert C Chan; Roberta W Pang; Ronnie Poon; Sheung-Tat Fan; Thomas Yau
Journal:  Oncologist       Date:  2011-12-01

3.  Comparison of hepatic arterial infusion chemotherapy and sorafenib in elderly patients with advanced hepatocellular carcinoma: A case series.

Authors:  Tomoyuki Nemoto; Hidetaka Matsuda; Takuto Nosaka; Yasushi Saito; Yoshihiko Ozaki; Ryoko Hayama; Tatsushi Naito; Kazuto Takahashi; Kazuya Ofuji; Masahiro Ohtani; Katsushi Hiramatsu; Hiroyuki Suto; Yasunari Nakamoto
Journal:  Mol Clin Oncol       Date:  2014-08-05

4.  Hepatocellular carcinoma in Central Europe: prognostic features and survival.

Authors:  M Schöniger-Hekele; C Müller; M Kutilek; C Oesterreicher; P Ferenci; A Gangl
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

5.  Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival.

Authors:  Gengo Tsukioka; Satoru Kakizaki; Naondo Sohara; Ken Sato; Hitoshi Takagi; Hirotaka Arai; Takehiko Abe; Mitsuo Toyoda; Kenji Katakai; Akira Kojima; Yuichi Yamazaki; Toshiyuki Otsuka; Yutaka Matsuzaki; Fujio Makita; Daisuke Kanda; Katsuhiko Horiuchi; Tetsuya Hamada; Mieko Kaneko; Hideyuki Suzuki; Masatomo Mori
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

Review 6.  Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Authors:  D Germano; V Tinessa; E Barletta; L Cannella; B Daniele
Journal:  Drugs Aging       Date:  2013-11       Impact factor: 3.923

7.  Prognostic factors of hepatocellular carcinoma patients treated by transarterial chemoembolization.

Authors:  Jun Xiao; Guojian Li; Shuhan Lin; Ke He; Hao Lai; Xianwei Mo; Jiansi Chen; Yuan Lin
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

8.  Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Yun-Hsuan Lee; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

Review 9.  Cirrhotic patients and older people.

Authors:  Paul Carrier; Marilyne Debette-Gratien; Jérémie Jacques; Véronique Loustaud-Ratti
Journal:  World J Hepatol       Date:  2019-09-27

10.  Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.

Authors:  Saur Hajiev; Elias Allara; Leila Motedayеn Aval; Tadaaki Arizumi; Dominik Bettinger; Mario Pirisi; Lorenza Rimassa; Tiziana Pressiani; Nicola Personeni; Laura Giordano; Masatoshi Kudo; Robert Thimme; Joong-Won Park; Tamar H Taddei; David E Kaplan; Ramya Ramaswami; David J Pinato; Rohini Sharma
Journal:  Br J Cancer       Date:  2020-10-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.